Santhera Pharmaceuticals Holding Full Year 2024 Earnings: CHF3.69 loss per share (vs CHF5.18 profit in FY 2023)

Santhera Pharmaceuticals Holding (VTX:SANN) Full Year 2024 Results

Key Financial Results

• Revenue: CHF39.1m (down 62% from FY 2023).
• Net loss: CHF42.0m (down by 177% from CHF54.8m profit in FY 2023).
• CHF3.69 loss per share (down from CHF5.18 profit in FY 2023).

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Santhera Pharmaceuticals Holding's share price is broadly unchanged from a week ago.

Risk Analysis

It's necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with Santhera Pharmaceuticals Holding (at least 1 which is concerning), and understanding them should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.